ChinaBio® Today Articles

Welcome to the ChinaBio® Today store. As a service to our readers, we offer access to individual articles for only $5.00 (USD) each. Of course, a subscription is only $20/mo, so you may prefer to subscribe. If so, click on Subscribe in the menu.

Browse

All Products

Viewing all 5448 products

View All
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
Next

Apollomics Merges with SPAC to List on NASDAQ; Climbs 121% Higher in Trading

$5.00

Ablaze Pharma Acquires China Rights to Targeted Radiotherapy Drug for Liver Cancers

$5.00

SciNeuro Signs Up Secarna to Discover Antisense Oligonucleotide Therapies for Neurology Targets

$5.00

ImmVira Approved to Start Trials of Oncolytic Virus Candidate for Malignant Glioma

$5.00

Pharmaron Receives $186 Million Grant to Expand UK Cell/Gene Therapy Manufacturing

$5.00

Junshi Forms Commercialization JV with Rxilient to Market PD-1 in Southeast Asia

$5.00

SalubrisBio Reports $35 Million Infusion from Parent for Novel Biologic Drugs

$5.00

OncoVent Sells Taiwan Rights to Ovarian Cancer Candidate for $11 Million

$5.00

ArriVent Closes $155 Million Round to In-license US Rights for China Drugs

$5.00

YS Biopharma Says PIKA COVID-19 Vaccine Offers Superior Immunogenicity

$5.00

Everest Forms Renal Research Partnership with Guangdong Medical Academy

$5.00

F-star Partners Second Early-Stage Tetravalent Bispecific Antibody with Takeda

$5.00

Transcenta Starts US Trials of Gremlin1 mAb for Prostate and Colorectal Cancer

$5.00

Highlightll Out-licenses Dual Inhibitor for Parkinson’s in $970 Million Deal

$5.00

Joincare to Develop TaiGen’s Pan-Flu Therapy in Greater China

$5.00

Boan Biotech Files China BLA for Bone Metastases Biosimilar

$5.00

280Bio Showcases Preclinical Findings for Novel KRAS Inhibitor

$5.00

Connect Biopharma’s IL-4Rα Antibody Effective in Atopic Dermatitis Patients

$5.00

Gracell Closes Cell Therapy Deal with Seagen; No Details Released

$5.00

ArkBio and Scripps Research Extend Partnership for Novel Respiratory Candidate

$5.00

Base Biotech Raises “Tens of Millions of Dollars” in A1 Round for Base Editing

$500.00

Everest Approved to Launch Antibiotic in China for Intra-Abdominal Infections

$5.00

Mabwell Starts Trials of mAb to Regulate Iron Homeostasis In Vivo

$5.00

Simcere to Test TNRF2 mAb in Combination with MSD’s Keytruda for Solid Tumors

$5.00

Everest’s In-licensed Kidney Drug Meets Endpoints in Phase III Trial

$5.00

Bio-Thera Starts Phase I Trial of Nectin-4 ADC for Solid Tumors

$5.00

Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million

$5.00

Luye Enrolls Last Patient in Phase III Trial of Eylea Biosimilar

$5.00

Allorion Raises $50 Million for Oncology/Autoimmune Precision Medicines

$5.00

AusperBio Starts New Zealand Phase I Trial of Novel Therapy for CHB

$5.00

Ambrx Partner Says HER2 ADC Ups Progression-Free Survival in Breast Cancer Trial

$5.00

Ractigen Granted Orphan Drug Status for Use of Novel siRNA in ALS

$5.00

CFIUS Approves Sino Biopharm’s Acquisition of F-Star after Nine Month Wait

$5.00

JW Therapeutics Announces CAR-T Trial as First-Line B-Cell Lymphoma Therapy

$5.00

JW Therapeutics Announces CAR-T Trial as First-Line B-Cell Lymphoma Therapy

$5.00

Rinua Gene Raises $14.5 Million in Pre-A+ Round for mRNA Drugs

$5.00

Harbour BioMed mAb Posts Positive Results in Phase III Myasthenia Gravis Trial

$5.00

JW Therapeutics Starts China Trial of T-cell Immunotherapy for Liver Cancer

$5.00

Transcenta Reports Immuno-PET Diagnoses CLDN18.2 Levels in Gastrointestinal Tumors

$5.00

Abbisko Out-Licenses Precision EGFR-TKI Medicine to Allist in $188 Million Deal

$5.00

TandemAI Raises $35 Million for AI/WetLab Drug Discovery Operations

$5.00

Immorna Raises $100 Million for Clinical Trials of Novel RNA Candidates

$5.00

Atom Bioscience Says Gout Treatment Meets Phase II Efficacy/Safety Endpoints

$5.00

Shanghai Oricell Raises $45 Million to Take Cellular Immunotherapies to US

$5.00

Junshi Reports anti-PCSK9 mAb Lowers Cholesterol in Phase III Trials

$5.00

Kelun Biotech Plans Hong Kong IPO to Develop ADCs and Other Products

$5.00

Chipscreen Signs $72 Million Deal for Eucure Bispecific Immunotherapy

$5.00

BeiGene’s PD-1 Approved in China for Tenth Indication, Gastric Cancer

$5.00

InnoCare-Keymed JV Starts China Trial of Novel CCR8 Immunotherapy

$5.00

Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement

$5.00

Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer

$5.00

Kinnate, a Precision Oncology Company, Pays $24 Million to Buy Out JV Partners

$5.00

Shenzhen Fapon Bio Starts US Trial of CD47 mAb for Advanced Malignancies

$5.00

InnoCare’s $937 Million MS Deal Falls Apart as Biogen Returns Rights

$5.00

Neurophth Completes Dosing in Phase III Trial of Gene Therapy for Hereditary Blindness

$5.00

Frontera Therapeutics Begins Trials for Three Leading Gene Therapy Candidates

$5.00

Innovent Starts China Trial of Novel mAb as Extended-Dose Psoriasis Therapy

$5.00

Junshi/Coherus Report PD-1 Effective in US Trial for Nasopharyngeal Carcinoma

$5.00

Henlius Biotech Reports US Accepts Herceptin Biosimilar BLA for Review

$5.00

Harbour BioMed Out-Licenses US Rights for Bispecific in $588 Million Deal

$5.00

Clover Launches COVID-19 Vaccine in China as Second Booster Dose

$5.00

CSPC Pharma Out-Licenses Nectin-4 ADC to Corbus in $692 Million Deal

$5.00

Wondercell Closes $14 Million in Angel Funding for Immune Cell Therapies

$5.00

Boan Biotech Starts China Trial of Anti-CD25 Antibody for Solid Tumor Cancers

$5.00

CANbridge Acquires Global Rights to Rare Disease Therapy from UMass

$5.00

ImmVira Posts Positive Data from Trial of Oncolytic Virus Injection for Melanoma

$5.00

Technoderma Starts US Trial of JAK1/Tyk2 Inhibitor for Atopic Dermatitis

$5.00

GenScript ProBio Forms Partnership to Expedite Novel Bio Immunitas Products

$5.00

Asieris Collaborates with ReviR to Discover RNA Candidates for Genitourinary Tumors

$5.00

China to Ban Export of Cutting-Edge Cell Therapy Technologies

$5.00

Results from InnoCare’s BTK Lymphoma Trial Published in Hematology Journal

$5.00

JiXing Buys Global Rights for Hypertension Candidate from PhaseBio

$5.00

Structure Stages Expanded $161 Million IPO for Novel Small Molecules

$5.00

Gracell Biotech to Start US Trial of Dual-Targeting CAR-T Therapy for Myeloma

$5.00

AnHeart to Use Guardant’s Assays for NSCLC Trials of ROS1 Inhibitor

$5.00

NeuShen and UMass Partner To Develop Gene Therapy for ALS

$5.00

Nervtex AI Device Approved in China to Diagnose Parkinson’s

$5.00

CS Pharma Acquires China Rights to Fibrosis Drug in $336 Million Agreement

$5.00

CARsgen to Test Claudin18.2 mAb with Roche’s PD-L1 for Gastric Cancer

$5.00

Help Therapeutics to Start Trial of Universal Cell Therapy for Heart Failure

$5.00

HuidaGene’s CRISPR Therapy Approved to Start US Trial for Inherited Retinal Disease

$5.00

Legend Reports CAR-T Meets PFS Endpoint as Second-line Therapy for MM

$5.00

HBMAT, a Harbour Biomed JV, Closes Seed Round for Novel Endocrine Therapies

$5.00

Akeso Approved to Market PD-1 in China as First-Line NSCLC Therapy

$5.00

Junshi Bio’s NDA for COVID-19 Therapy Accepted for Review in China

$5.00

HutchMed Out-licenses Rights for VEGFR Drug to Takeda in $1.1 Billion Deal

$5.00

Mabwell Out-licenses Rare Disease Drug to Disc Medicine for $412.5 Million

$5.00

Tigermed Expands Footprint and Services by Acquiring Marti Farm, a Croatian CRO

$5.00

Aprinoia, a Neurodegenerative Company, to be Acquired by $280 Million SPAC

$5.00

Nanjing IASO Bio Raises $75 Million to Develop/Commercialize CAR-T Assets

$5.00

GenScript ProBio -- a mAb, Cell & Gene Therapy CDMO -- Raises $224 Million

$5.00

Henlius anti-PD-1 Approved to Launch in China for Small Cell Lung Cancer

$5.00

CARsgen Signs $181 Million Deal to Commercialize CAR-T in China with Huadong

$5.00

Harbour Biomed to Start US Trials of Novel B7H7 Immunoncology Asset

$5.00

Bio4t2 Starts China Trial of BT-001 Antigen CAR-T for Solid Tumor Cancers

$5.00

Visen Pharma Completes Phase III Trial of Therapy for Rare Thyroid Disease

$5.00

Evopoint Options-Out Rights for Pre-clinical Solid Tumor ADC to AmMax

$5.00

Takeda Approved to Launch Targeted Drug for NSCLC with Mutations in China

$5.00

Chengdu Qitan Raises $101 Million for Nanopore Sequencing Devices

$5.00

Dizal’s NDA Filing for NSCLC Therapy Accepted for Review in China

$5.00

Innovent Starts China Phase III Trial for Dual Agonist Diabetes Therapy

$5.00

Immune-Onc Adds $25 Million to B Round for Novel Myeloid Checkpoint Inhibitors

$5.00

Duality Licenses ADC Platform to Adcendo for Mesenchymal Cancer Program

$5.00

WuXi Biologics Signs $1.5 Billion Pact with GSK for Four Novel TCE Antibodies

$5.00

HighTide Closes $107 Million Round for Metabolic/Digestive Disease Candidates

$5.00

ArriVent in Hunt for $145 Million to Finance US In-licensing Operations

$5.00

Transcenta Approved to Start China Trials of Gremlin1 mAb for Prostate Cancer

$5.00

Biocytogen Out-Licenses Global Rights for mAb Candidates to Hansoh

$5.00

ProfoundBio Starts US Trial of ADC in Solid Tumor Cancers

$5.00

Boan Stages $20 Million Hong Kong IPO for Biosimilar/Novel mAb Drugs

$5.00

InnoCare Approved to Launch Cytolytic CD-19 Immunotherapy in Hong Kong

$5.00

Everest Starts Operations in New mRNA Vaccine Production Facility

$5.00

Ablaze Pharma Forms CDMO Partnership with Yonghe for Radiopharmaceuticals

$5.00

Junshi Out-licenses Middle East/North African Rights for PD-1 to Hikma Pharma

$5.00

WuXi XDC to Offer GeneQuantum’s Platforms for Bioconjugate Development

$5.00

MindRank OK’d to Start US Trials of GLP-1 Candidate for Obesity and Diabetes

$5.00

TenNor Raises $10 Million for Conjugate Infectious Disease Products

$5.00

IASO Approved to Start US Trials of Lead Drug, a BCMA CAR-T

$5.00

Kelun-Biotech Signs $9.5 Billion Deal with Merck for Seven ADC Candidates

$5.00

XtalPi Collaborates with Singapore’s EDDC to Discover NSCLC Candidates

$5.00

Shanghai Group Leads $20 Million Round for Israel’s Biomica, a Microbiome Company

$5.00

Staidson Bio In-Licenses mAb Complement Therapy for COVID in $10 Million Deal

$5.00

LianBio Sells Rights for RSV Therapy to Pfizer in $155 Million Deal

$5.00

Kira Pharma Starts China-Australia Trials of Dual Complement Pathway Candidate

$5.00

Innovent Enters $95 Million Agreement to In-License Gout Treatment

$5.00

Alternative Bio Lands $15 Million to Develop Oncology Drugs based on Novel Enzymes

$5.00

Suzhou 4B Technologies Closes $14 Million Pre-B Financing for Neuro Drugs

$5.00

BeiGene Says its BTK Inhibitor Out-Performs Janssen’s Imbruvica

$5.00

Boston Scientific Pays $523 Million for Control of Acotec, a Beijing Device Company

$5.00

Nanjing Biosion Forms ADC Discovery Collaboration with Boston’s ImmunoGen

$5.00

HitGen Forms Partnership with Nitrase to Develop Novel Enzyme Inhibitors

$5.00

CARsgen Files NDA for China Approval of CAR-T Based on Phase II Data

$5.00

GenScript to Build Synthetic Biology Library with Singapore’s Allozymes

$5.00

Ascletis Pharma to Start China Trials of Protease Inhibitor to Treat COVID-19

$5.00

Hexaell to Start China Trial of Novel Drug-Device for Chronic Liver Failure

$5.00

China Approves Covid Vaccines from Two Companies, Sinocelltech and Clover

$5.00

Innovent Starts China Trials of In-licensed Oral Therapy for Skin Diseases

$5.00

Henlius and Innovent/Lilly: A Tale of Two PD-1 Candidates

$5.00

Boan Biotech’s IPO Application Accepted by Hong Kong Exchange

$5.00

Boston’s Regenta Raises $52 Million for RNA Drugs from China Investors

$5.00

Gland Pharma, a Fosun Subsidiary, to Buy French CDMO for $124 Million

$5.00

Pediatrix Acquires Atopic Dermatitis Therapy in $96 Million Agreement

$5.00

Full-Life Enters $245 Million Deal to Acquire Focus-X, a Radiopharma Company

$5.00

Biocytogen Signs Option to Out-License Three Antibodies to ADC Therapeutics

$5.00

XtalPi and CK Life Sciences Partner to Discover Therapeutic Tumor Vaccines

$5.00

Lyvgen to Start Phase II Trial of mAb with BMS’s PD-1 Keytruda

$5.00

Wanbang Biopharma Adds Animal Rights to Agreement for Diabetes Therapy

$5.00

AnchorDx Starts US Trial of Non-Invasive Test for Bladder Cancer

$5.00

Nona, a Harbour BioMed Subsidiary, to Discovery Immunotherapies for Dragonfly

$5.00

Luye Pharma’s Long-Acting Schizophrenia Drug Meets Endpoints in US Trial

$5.00

IASO Forms Collaboration with Umoja for Allogenic CAR-T Therapies

$5.00

Triastek to Start US Trials of Third 3D Printed Therapy

$5.00

Everest’s NDA for Renal Disease Therapy Accepted in China

$5.00

Tenacia Signs $266 Million Agreement with Marinus for Seizure Drug

$5.00

SynRx Raises $14 Million to Develop Drugs for Solid Tumor Cancers with DNA Damage

$5.00

Evive Sells US Rights for Neutropenia Therapy to Aerotech in $236.5 Million Deal

$5.00

Simcere Enters $50 Million Deal for China Rights to Novel Insomnia Therapy

$5.00

Hansoh Enters $207 Million Agreement for Biotheus EGFR/MET Bispecific

$5.00

WuXi Vaccines Acquires Suzhou Manufacturing Facility from Harbour BioMed

$5.00

Lupeng Pharma Closes 2nd $35 Million Pre-B Tranche for Small Molecule Drugs

$5.00

Nuance Pharma to Start China Phase III Trial of RSV Vaccine in Adults

$5.00

EQRx Retracts Promise to Bring Low-Cost China Drugs to US

$5.00

Harbour BioMed Forms Immunotherapy Discovery Collaboration with Moderna

$5.00

Zenas BioPharma Raises $118 Million for Global Autoimmune Portfolio

$5.00

YS Biopharma to Start Trials for PIKA COVID-19 Vaccine in US

$5.00

NovoCodex Starts China Trial of anti-CD70 ADC in Solid Tumors

$5.00

Sirnaomics Starts Trial of Lead siRNA Therapy for Fat Reduction

$5.00

Insilico Announces Six-Drug, $1.2 Billion AI Drug Discovery Deal with Sanofi

$5.00

XellSmart Raises $27.6 Million for Low-Cost Stem Cell Therapies

$5.00

Neurophth Enters $140 Million Gene Therapy Collaboration with Cyagen

$5.00

Asieris Starts China Phase III Trial of Bladder Cancer Diagnostic

$5.00

China Allows BioNTech to Import mRNA COVID Vaccine – for Expats Only

$5.00

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bi-specific

$5.00

CBC Group Plans $137 Million Shanghai Biopharma Center

$5.00

Kira Says First-in-Human Trial Shows Complement Candidate Effective

$5.00

Beijing Immunochina Closes Series D+ with at least $28 Million for CAR-T Drugs

$5.00

Eucure Partners CD40 Antibody for Tri-Specific Drug with Korea’s ISU ABXIS

$5.00

China Blocks GSK Generic BPH Drug Due to Safety Concerns

$5.00

Beihai Raises $27 Million to Support Increased Solubility Oncology Drugs

$5.00

CorreGene Closes $14 Million Pre-A+ round for Novel TCR Drugs

$5.00

JHM Bio Closes $28 Million Round for Biologic Product Portfolio

$5.00

Fosun Kite’s NDA Accepted for Second Indication of CAR-T in China

$5.00

JW Therapeutics Partners with 2seventy bio to Develop T Cell Immunotherapies

$5.00

Salubris and Anlong to Co-develop Nucleic Acid Hypertension Drug

$5.00

ImmVira Closes C+ Tranche, Will Keep Round Open for Two Months

$5.00

Ascletis Files US IND to Test COVID Antiviral for Monkeypox

$5.00

Celgenyx Closes $14 Million A Round for Off-the-Shelf Cell Therapies

$5.00

Akeso Receives Breakthrough Designation for PD-1/VEGF Bispecific

$5.00

Maxinovel Raises $14 Million for Novel Small Molecule Portfolio

$5.00

Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates

$5.00

Hrain Biotech Plans $352 Million Shanghai STAR IPO for Novel CAR Candidates

$5.00

Everest's Partner, Providence Therapeutics, Reports mRNA Vaccine Matches Pfizer’s

$5.00

Everest's Partner, Providence Therapeutics, Reports mRNA Vaccine Matches Pfizer’s

$5.00

Eucure Biopharma Licenses Antibody to Syncromune for Personalized Cancer Therapy

$5.00

Zhiyi Bio to Start US Trial of Live Biotherapy for Chemotherapy-Induced Diarrhea

$5.00

Gracell Starts China Trial of Donor-Derived CD-19 CAR-T for Leukemia

$5.00

Innovent Publishes Positive Weight Loss Data from Trial of GLP-1/Glucagon Agonist

$5.00

Bio-Thera Starts China Trial of mAb Biosimilar for Asthma

$5.00

LianBio Stops China Trial of Liver Cancer Drug After Helsinn Asks FDA to Withdraw Approval

$5.00

Accutar Starts China Phase I Trial of AI-developed Protein Degrader for Breast Cancer

$5.00

Harbour BioMed Announces $140 Million Deal to Out-license Autoimmune Therapy to CSPC

$5.00

WuXi Biologics to Partner with Toregem to Develop mAb for Tooth Regeneration

$5.00

Jemincare Out-licenses Prostate Cancer Drug to Roche in $650 Million Deal

$5.00

IASO Signs $162 Million Agreement to Out-License CD19 Binder to Cabaletta For CAR-T

$5.00

JW Therapeutics Approved to Launch CAR-T for Second Lymphoma Indication

$5.00

Innovent Approved to Launch Oncology Drug for Cancers with RET Gene Fusions

$5.00

Tracon Pharma Says PD-L1 Passes Interim Safety Test in Sarcoma Trial

$5.00

Ascletis Doses First Patient in China Trial of THRβ Agonist for NASH

$5.00

Transcenta OK’d to Start US Trials of MASP2 mAb for Kidney Disease

$5.00

Connect Reports Positive Results from Pivotal Trial of its Atopic Dermatitis Therapy

$5.00

Moderna and China at Impasse over Selling mRNA COVID Vaccine in China

$5.00

Kira Pharma to Start Phase II Trials of Biologic Targeting Two Complement Pathways for Severe Lupus

$5.00

Biosyngen’s IND Accepted in China for T Cell Treatment of Nasopharyngeal Cancer

$5.00

YishengBio Announces Merger with NASDAQ SPAC Company at $834 Million Value

$5.00

Harbour BioMed Starts Phase I Trial of Biologic Therapy for Asthma

$5.00

Simcere Out-Licenses Autoimmune Candidate to Almirall in $507 Million Deal

$5.00

NeuShen Raises $20 Million in Pre-A Round for CNS Gene Therapy/Small Molecule Drugs

$5.00

Xuanzhu Biopharm, a Sihuan Subsidiary, Files to Raise $345 Million in Shanghai STAR IPO

$5.00

SynerK Partners with SciWind to Develop siRNA Drugs for Liver and Metabolic Diseases

$5.00

Hansoh Acquires China Rights to Osteoarthritis Therapy in Deal Worth $63 Million-Plus

$5.00

Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront

$5.00

Huisheng Biopharma Closes $70 Million Round for Diabetes Drug Portfolio

$5.00

Bioheng Publishes Positive Results for Universal CAR-T in Hematological Malignancies

$5.00

CASI Divests 12% Stake in Juventas, its CAR-T Partner, for $34 Million

$5.00

MilliporeSigma Opens Viral Clearance Lab in Shanghai, Part of a $29 Million Project

$5.00

Sino Biopharm Signs $307 Million Deal with Inventiva for NASH Therapy

$5.00

Keymed’s Claudin 18.2 ADC Granted China Breakthrough Status for Gastric Cancer

$5.00

RemeGen Reports Positive Results from Confirmatory Trial of Lupus Therapy

$5.00

Frontera Approved to Start China Trial of Gene Therapy for Inherited Retinal Degeneration

$5.00

Immuno Cure Acquires Partner Teresa Healthcare, an Electroporation Company

$5.00

Biocytogen and FineImmune Partner on Cell Therapies Targeting Intracellular Antigens

$5.00

Arnatar Biomedical Raises $15 Million in Seed Round for RNAi Therapies

$5.00

Belite Bio Starts China Trial of Therapy for Stargardt, an Inherited Renal Disease

$5.00

Apollomics, a US-China Biopharma, will Merge with SPAC to List on NASDAQ Exchange

$5.00

Lepu Medical, a Medical Device Company, Raises $224 Million by Listing on Swiss Exchange

$5.00

METiS Acquires Rights to Pan-RAF Inhibitor in $482 Million Agreement

$5.00

Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing

$5.00

Great Bay Bio, a Hong Kong CRO, Closes $15 Million Round for AI-based Bioprocessing

$5.00

Celregen Therapeutics In-Licenses iPS Therapy for Cornea Transplants in $100 Million Deal

$5.00

Worg Pharma Completes $57 Million Series B for Novel Allergy and Autoimmune Therapies

$5.00

Advanced MedTech Acquires WIKKON, a Shenzhen Urology Device Maker

$5.00

US Blocks Asymchem’s $58 Million Acquisition of Boston’s Snapdragon

$5.00

Redbud Closes $10 Million Round for China-US Clinical CRO Services

$5.00

I-Mab Says CD47 Inhibitor Effective in Myelodysplastic Syndrome

$5.00

Frontier Biotech Raises $29 Million for Novel COVID-19 Therapy

$5.00

CanSino Inhaled COVID-19 Vaccine Approved in China as Booster

$5.00

CanSino Inhaled COVID-19 Vaccine Approved in China as Booster

$5.00

CellOrigin and Qilu to Develop Off-the-Shelf CAR-Macrophage Immunotherapies

$5.00

CASI and BioInvent Start China Trial of FcγRIIB Inhibitor for NHL

$5.00

BoomRay Raises $43 Million for Novel Diagnostic/Therapeutic Radionuclide Medicines

$5.00

Vernalis Collaborates with Unison to Discover Drugs for “Undruggable” Bacterial Target

$5.00

Neukio Bio Completes $50 Million Round for Allogenic CAR-T Therapies

$5.00

DAC Biotech to Discover Five ADCs in Partnership with Janssen Biotech

$5.00

Hangzhou Innoforce and Hibiscus Join to Advance Mayo Clinic’s Cell and Gene Therapies

$5.00

E-nitiateBio Closes $15 Million Round to Support Autoimmune Portfolio

$5.00

Asieris Acquires Rights to Heart Failure Therapy from Acorda

$5.00

I-Mab to Concentrate on Five Clinical-Stage Candidates, Out-licensing International Rights

$5.00

Sirnaomics Reports 100% Complete Response for Lead siRNA Candidate

$5.00

UniCar Closes C Funding for “Safe” CAR-T Dual Target Candidate

$5.00

RedCloud Doses NSCLC Patient in China Trial of Next-Gen EGFR TK

$5.00

Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs

$5.00

Bao Pharma Raises $100 Million in Series B Round for Protein/Antibody Drugs

$5.00

AlphaBio Completes Trials of Therapy for NSCLC with CNS Metastases

$5.00

Clover Plans to Add Adolescents to List of Groups Approved for COVID-19 Vaccine

$5.00

Lee’s Pharm Signs $78.9 Million Deal for RDS Drug/Device for Pre-Term Infants

$5.00

Ranok Starts Trials of BRD4 Protein Degradation Therapy for Solid Tumors

$5.00

Hansoh Forms $270 Million Partnership with GHDDI for COVID-19 Therapy

$5.00

I-Mab to Start $40 Million Company/Management Share Repurchase Program

$5.00

Porton Advanced Raises $80 Million for Gene and Cell Therapy CDMO Operations

$5.00

Sirnaomics Starts US Trial of siRNA Therapy for Squamous Cell Skin Cancer

$5.00

IASO to Start China Trial of Injected CAR-T Therapy for Autoimmune Disease

$5.00

Accutar’s Chimeric Degrader OK’d for Prostate Cancer Trials in China

$5.00

Jemincare Out-Licenses Prostate Cancer Candidate to Genentech for $650 Million

$5.00

Wyze Biotech Closes A Rounds with $30 Million for Universal Immune Cell Products

$5.00

Everest Returns Greater China Rights for Trodelvy to Gilead for $455 Million

$5.00

SinocellTech Says Anti-CD20 mAb Shows Non-Inferiority to Genetech’s Rituxan

$5.00

Bennu Bio Closes $15 Million Funding for T-Cell Therapies

$5.00

GenoImmune, a GBI Company, Completes Funding for NeoAntigen Cell Therapies

$5.00

EQRx Starts US Phase III Trial of Hansoh’s EGFR for NSCLC

$5.00

Frontier Reports Positive Results from Early Trial of COVID-19 Therapy

$5.00

Insilico Closes $35 Million D2 Round; Will Expand AI Beyond Drug Discovery

$5.00

Axcynsis Opens Shanghai R&D Center; Raises $15 Million

$5.00

LianBio Completes Enrollment of Phase III Trial for Cardiomyopathy Therapy

$5.00

Arbele Starts Australian Trial of CDH17xCD3 Bispecific for GI Cancers

$5.00

Hansoh Enters $170 Million Agreement for Endometriosis/Uterine Fibroid Therapy

$5.00

Inmagene and HutchMed Start Global Trial of BTK Inhibitor

$5.00

Epigenic Therapeutics Raises $20 Million in Angel and Pre-A Rounds for Epigenetic Drugs

$5.00

ImmVira Granted US Orphan Drug Status for Oncolytic Virus Candidate in Glioma

$5.00

Innovent to Partner two Sanofi Cancer Assets in China; Sanofi Invests $305 Million in Innovent

$5.00

Genuine Biotech Files for Hong Kong IPO to Support Novel Drugs Portfolio

$5.00

Radiopharm Forms Collaboration to Develop PD-L1 Diagnostic/Therapeutic Antibody

$5.00

ProfoundBio Cleared to Start US Trials of ADC for Solid Tumor Cancers

$5.00

Ablaze Plans $100 Million Facility in Chengdu Medical City for Targeted Radiation Therapies

$5.00

Zenas to Start China Trials of Thyroid Eye Disease Therapy

$5.00

Sironax Closes $200 Million Round for Novel Degenerative Disease Therapies

$5.00

Structure Therapeutics Closes $33 Million for Novel Small Molecule Drugs

$5.00

OriCell Closes $120 Million Round for Cell Therapies and Bispecific Candidates

$5.00

GluBio Completes $22 Million Funding for Protein Degradation Candidates

$5.00

CSPC Pharma Out-Licenses Claudin18.2 ADC in Deal with $1 Billion in Commercial Milestones

$5.00

Maxvax Completes $74 Million Series B for China Vaccine Development

$5.00

Kelun-Biotech Out-Licenses Second ADC Candidate to MSD in $936 Million Deal

$5.00

BridGene Closes $38.5 Million Funding from China Investors for Novel Small Molecule Targets

$5.00

Legend Bio Plans to Raise $250 Million in Public Offering of Shares

$5.00

HanX and Lepu Approved to Launch PD-1 mAb for Colorectal Cancer

$5.00

InvestisBio Completes $296 Million IPO on the Shanghai STAR Board

$5.00

Rona Therapeutics In-licenses Exclusive Global Rights to Sanofi’s siRNA Platform

$5.00

WuXi Biologics and WuXi AppTec to Spend $2.8 Billion to Build Separate Singapore Facilities

$5.00

Luzhu Biotech Files for HK IPO to Support Shingles Vaccine and Adalimumab Biosimilar

$5.00

NeuroFront Acquires Non-Opioid Neuropathic Pain Killer for $130 Million

$5.00

ImmVira Says IV Administration of Oncolytic Herpes Simplex Virus Shows Promise

$5.00

Frontera Closes $160 Million B Round for US-China Gene Therapy Development

$5.00

Ascentage-Innovent NDA Accepted for Priority Review as Chronic Myeloid Leukemia Therapy

$5.00

Innovent Says Type 2 Diabetes Therapy Meets Glycemic/Weight Loss Endpoints

$5.00

Antengene to Test its Bispecific with Celularity’s Stem Cell Natural Killer Cell Therapy

$5.00

Merck’s Uptune Program to Back Asia Health/Technology Startups with €100,000

$5.00

Simcere Approved to Launch Myelosuppression-Prevention Drug in China

$5.00

Suzhou CStone Pharma Engages Goldman Sachs to Explore Sale of Company

$5.00

CStone Approved to Launch RET Inhibitor in Hong Kong for NSCLC

$5.00

Epic Bio Completes $55 Million Funding Led by HK’s Horizon to Modify Gene Expression

$5.00

Triastek and Lilly Collaborate on Using 3D Printing for Programed Release of GI Drugs

$5.00

Bio-Thera Starts China Trials of ADC for Solid Tumors

$5.00

Connect to Use Early Results from China Phase III Trial of Atopic Dermatitis Therapy

$5.00

Tasly Forms JV to Commercialize Confocal Laser Endomicroscopy Device

$5.00

Sinopharm May Bid $1 Billion for Shanghai’s BBI, a Research Products Company

$5.00

Overland ADCT Starts China Trial of ADC for B-cell Lymphoma

$5.00

Precision Autoimmune Therapies Raises $21 Million to Develop Anti-CD38 Program

$5.00

BeiGene Collaborates with InnoRNA to Develop mRNA Therapeutics

$5.00

Zhiyi Bio Raises $45 Million for Live Biotherapeutic Products Aimed at IBS and Cancer

$5.00

SunHo Starts Trial of Dual Immunocytokine Therapy for Solid Tumor Cancers

$5.00

Sequoia Raises $9 Billion for Healthcare/Tech Investments in China

$5.00

Arctic Vision Starts China Phase III Trial of Farsightedness Therapy

$5.00

ClinChoice, a Global Clinical CRO, Raises $150 Million from China Investors

$5.00

Brii Bio In-licenses China Rights to Second HBV mAb from Vir

$5.00

Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients

$5.00

Clover Bio’s COVID Vaccine Effective as Booster Against Omicron Variants

$5.00

BeiGene’s Phase III Data Shows PD-1 Effective as First Line Therapy for Esophageal Carcinoma

$5.00

Suzhou Ascentage to Start US Trial of Novel EED Protein Inhibitor

$5.00

Akeso Approved to Launch Dual Checkpoint Inhibitor for Cervical Cancer

$5.00

GenFleet to Receive Royalty Rights for Conducting China Trial of BioLineRx Cancer Drug

$5.00

Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal

$5.00

Shanghai Zai Lab Raises Hong Kong Listing to Primary Status

$5.00

Innovent/Lilly Announce China Approval for Sixth Indication of PD-1 Drug

$5.00

Harbour BioMed to Start US Trials of Novel Bispecific for Solid Tumor Cancers

$5.00

Reistone Completes $100 Million A Round for Inflammatory Disease Drugs

$5.00

Genor Partners with Abogen to Develop mRNA Products for Oncology Needs

$5.00

Sino Biopharm’s invoX Acquires F-Star, a UK Bispecific Company, for $161 Million

$5.00

AstraZeneca to Build Qingdao Regional Headquarters with Rare Disease Innovation Center

$5.00

Xuanzhu Out-Licenses China Rights for Two Antibiotics in $66 Million Deal

$5.00

InnoCare Starts China Trial of SHP2 Inhibitor for Solid Tumors

$5.00

OcuMension Approved to Launch Novel Uveitis Therapy in China

$5.00

Shenzhen's AxBio Raises $100 Million for Low-Cost, High Precision Sequencing Machines

$5.00

MegaRobo Raises $300 Million for Automated Drug Lab Systems and Robots

$5.00

CANbridge Says Anti-C5 mAb Shuts Down Complement Activity

$5.00

Joincare Plans IPO on the SIX Swiss Stock Exchange

$5.00

Clover Starts Phase III Trial of COVID Vaccine as a Booster to Other Vaccines

$5.00

I-Mab’s Partner MorphoSys Out-Licenses Ex-China Rights for Two Oncology Candidates to HIBio

$5.00

WinHealth Acquires Two Rare Disease Therapies from Quoin Pharma

$5.00

Kangpu Doses First Patient in Phase IIa Trial for Protein Degradation Therapy

$5.00

Alphamab Starts China Trial of PD-L1/OX40 Bispecific for Solid Tumors

$0.00

Organon Pays $103 Million to Acquire Global Rights for Two Henlius Biosimilars

$5.00

META Raises $15 Million to Develop Small Molecule Immunometabolism Drugs

$5.00

Everest Approved to Launch ADC for Triple-Negative Breast Cancer in China

$5.00

Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers

$5.00

Chengdu Keymed Starts China Trial of Bispecific for Solid Tumor Cancers

$5.00

Shanghai Degron Raises $22 Million for Protein Degradation Drugs

$5.00

I-Mab Alters Collaboration with Ferring Pharma for Developing IBD Candidate

$5.00

OnCusp Acquires Global Rights (ex-China) to CDH6 ADC from Multitude Therapeutics

$5.00

Insilico Medicine Completes $60 Million Funding; Will Build Robotic Drug Discovery Lab

$5.00

Henlius Releases Positive Results for PD-1 as First-Line Therapy for SCLC

$5.00

NuProbe Raises $50 Million for Genomics and Molecular Diagnostics

$5.00

Insilico Starts China Trial of AI-Discovered Novel Fibrosis Therapy

$5.00

ProfoundBio Closes $70 Million Series A+ Funding for ADC and Immunotherapy Drugs

$5.00

Sihuan and CTTQ-Akeso Team up to Test AXL Inhibitor and PD-1 in Solid Tumors

$5.00

Vivo Capital Closes First Tranche of China Fund at $600 Million; Aiming for $1.5 Billion

$5.00

SciNeuro Acquires Rights to Lp-PLA2 Inhibitor from GSK for Alzheimer’s

$5.00

Hansoh Publishes Positive Results in ASCO Journal for Third-Gen EGFR-TKI Inhibitor

$5.00

IASO IND for CAR-T to Treat Autoimmune Disease Accepted in China

$5.00

Oncotelic Forms $50 Million Hong Kong JV to Develop Antisense Candidate

$5.00

Legend Bio to Launch CAR-T in Europe for Multiple Myeloma

$5.00

Full-Life Closes $37 Million Series A for Radiopharmaceutical Oncology Products

$5.00

Laekna Starts China-US Trials of AKT Kinase Inhibitor for Breast Cancer

$5.00

Junshi’s Novel SARS-CoV-2 Therapy Out-Performs Pfizer’s Paxlovid

$5.00

DongCheng Acquires Imaging Tracer to Predict Immunotherapy Efficacy

$5.00

CASI Signs $10 Million Out-licensing of CD38 for Autoimmune Indications to Tianshi

$5.00

CanSino One-Shot COVID Vaccine Accepted by WHO

$5.00

Fosun Acquires Novel Cancer Immunotherapy in $125 Million Deal

$5.00

CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy

$5.00

Belief BioMed Reports Positive Data for Hemophilia Gene Therapy

$5.00

Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor

$5.00

Bayer/Merck Cardiovascular Drug Approved for China Use

$5.00

Ascentage Oncology Drug Effective in Preclinical Tests for COVID Cytokine Storm

$5.00

Hengrui Launches Luzsana to Bring its Novel Medications to Global Markets

$5.00

Laekna Raises $61 Million for its 14-Drug Cancer/Liver Disease Portfolio

$5.00

Kelun Out-Licenses Global Rights for Candidate to Merck/MSD in $1.4 Billion Deal

$5.00

Henlius Out-licenses Latin American Rights for Three Biosimilars in $55 Million Deal

$5.00

Green Valley Stops Global Phase III Trial of its Novel China-Approved Alzheimer’s Drug

$5.00

Zenas Files China IND for mAb to Treat Thyroid Eye Disease

$5.00

Hengrui Reports PD-1 Combo Therapy Effective in Global Trial for Liver Cancer

$5.00

CARsgen Reports Positive Results for CAR T Therapy in Solid Tumor Cancers

$5.00

Coherus Returns Rights for Avastin Biosimilar to Innovent

$5.00

Zhimeng Bio Starts US Trials for Novel Epilepsy Therapy

$5.00

Zhaoke Signs $130 Million Deal for Two Eyedrop Near-Vision Treatments

$5.00

Ascletis Starts US Trial of PD-L1 as AIDS/HIV-1 Cure

$5.00

SCG to Start China/Singapore Trials of Cell Therapy for Hepatocellular Carcinoma

$5.00

Tonghua Dongbao Doses First Patient in China Phase III Trial of Ultra-Rapid Insulin

$5.00

InxMed Adds $15 Million B+ Funding for China/US Pivotal Trials of FAK Inhibitor

$5.00

Elpiscience Cleared for US Trials of Bispecific Immunotherapy in Solid Tumors

$5.00

Jemincare Out-Licenses Global Rights (ex-China) for Novel Pain Drug to Finland’s Orion

$5.00

Newsoara Ok’d to Start China Phase III Trial of Bowel Function Drug

$5.00

Zhifei Lvzhu In-Licenses Whooping Cough Vaccine from Intravacc

$5.00

Connect Plans to Partner Ulcerative Colitis Candidate After Disappointing Trial

$5.00

BeiGene Approved to Launch Bi-Specific in China for Pediatric Leukemia Patients

$5.00

Suzhou Kintor Starts US Trial of ALK-1 mAb for Hepatocellular Carcinoma

$5.00

What Biopharma Slowdown? OrbiMed Raising $1.1 Billion for Asia Companies; $4.75 Billion for Three Funds

$5.00

Hansoh Signs $218 Million Agreement with NiKang for Oncology Asset

$5.00

Inmagene Approved to Start US Trials of HutchMed Immune Disease Therapy

$5.00

Junshi and Coherus Undaunted by US Rejection of Partnered PD-1

$5.00

LianBio’s Partner BMS OK’d to Launch Cardiomyopathy Drug in US

$5.00

Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis

$5.00

Xbiome Acquires Global Rights to Microbiome Product for Ulcerative Colitis

$5.00

Chimera Bio Wins $7.5 Million Asia Award for Novel CAR-T Technology

$5.00

RVAC Completes B Round for mRNA Drugs, Bringing Total Raised to $140 Million

$5.00

Huadong Medicine Acquires Rights to Four Ashvattha Candidates for $45 Million

$5.00

I-Mab and VMS Partner to IPO a SPAC in HK for a China Life Science Company

$5.00

Viva Invests $60 Million in China RNAi JV it Formed with Arrowhead

$5.00

Sinorda and Porton Partner to Advance Cell and Gene Therapy Products

$5.00

Shanghai STAR Exchange Biologic and Medicine Index Launches May 9

$5.00

Lynk to Start China Trials of Novel Kinase Inhibitor for Psoriasis

$5.00

Binhui Raises $47 Million for Oncolytic Virus Products

$5.00

I-Mab Seeks Deal – Maybe Partnering a Drug, Maybe Selling the Company

$5.00

ImmVira to Test its 3-in-1 Virus Delivery Product with Roche’s MEK Inhibitor

$5.00

JW to Start China Trials of CAR-T for Pediatric/Young Adult Leukemia

$5.00

GeneQuantum Partners with Aimed Bio to Develop ADC for Brain Cancer

$5.00

Ascletis Reports Positive Preclinical Data from 3CLpro COVID Therapy

$5.00

Trevena Closes $40 Million Revenue-based Financing with CBC Affiliate

$5.00

Amoy to Develop Companion Diagnostics for AstraZeneca Drugs

$5.00

Bayer Precision Medicine Approved in China for NTRK Gene Fusion Cancers

$5.00

BeiGene Snags 8th China Approval for Tislelizumab, a PD-1 mAb

$5.00

Junshi PD-1 Granted US Orphan Designation for Small Cell Lung Cancer

$5.00

CStone Presents Preclinical Data on Tri-specific (PD-L1, 4-1BB, HSA) mAb

$5.00

AnPac Bio-Medical Raises $15 Million to Develop Early Cancer Detection Tests

$5.00

AffaMed and VistaGen Start China Phase III Trial of Social Anxiety Therapy

$5.00

InventisBio Reports Promising Data from KRAS G12C Trials

$5.00

LTZ Completes $17 Million Pre-A Raise for Immunotherapies

$5.00

Everest Medicines Signs MOU with CR Pharma to Form mRNA Company

$5.00

Harbour BioMed Out-licenses Bispecific to AstraZeneca in $350 Million Agreement

$5.00

ENSEM Raises $67 Million in A Round for Structure-Based Oncology Drugs

$5.00

GenFleet Out-Licenses CDK9 Inhibitor to Sellas in $150 Million Deal

$5.00

Pregene Out-licenses CAR-T to CellPoint for $22 Million in Near-Term Payments

$5.00

Innovent Reports Positive Data from Phase III Trial of PCSK-9 Cholesterol Drug

$5.00

Sirnaomics Starts US Trial of siRNA Therapy for Liver Fibrosis

$5.00

China Changes Policy: US Auditors Can Examine US-Listed China Companies

$5.00

CanSinoBIO Approved to Start China Trials of mRNA COVID Vaccine

$5.00

RemeGen Stages $410 Million Shanghai IPO; Trades Lower

$5.00

Zhongze Completes China Dose Escalation Trial for Schizophrenia Therapy

$5.00

CStone Starts US Trial of ROR1 Conjugate Drug for Lymphoma and Solid Tumors

$5.00

Hasten Closes $353 Million Deal to Distribute Five Takeda Drugs in China

$5.00

InnoRNA Raises $120 Million in B Round for mRNA Candidates

$5.00

Brii Bio Partners with Sinopharm to Distribute COVID mAb Therapy in China

$5.00

Biosion Out-Licenses Siglec-15 mAb for Solid Tumors in $226 Million Pact

$5.00

CANbridge NDA for Rare Disease Therapy Accepted in Taiwan

$5.00

Innovent Signs $45 Million Deal to Commercialize Two Lilly Oncology Drugs in China

$5.00

InnoCare Approved to Start Trials of JH2 Inhibitor for Autoimmune Diseases

$5.00

OBiO Completes Shanghai IPO for Gene-Cell CDMO Services; Trades 67% Higher

$5.00

Ascentage Granted US Rare Pediatric Disease Status for Neuroblastoma Therapy

$5.00

Recbio Plans to Raise $98 Million in a Hong Kong IPO for Vaccines

$5.00

Nuance In-licenses Adult RSV Vaccine in $225 Million Deal

$5.00

Simcere to Commercialize Lynk's JAK1 Inhibitor in China

$5.00

China and US May Solve De-Listing Problem

$5.00

Bioheng Approved to Start First China Trial of Universal CAR-T Therapy

$5.00

EdiGene Licenses IP to Treat Genetically Caused Hemoglobin Diseases

$5.00

Junshi Starts Global Phase III Trial of COVID-19 Therapy

$5.00

Junshi/Coherus Says PD-1 Meets Endpoints in US Phase III NSCLC Trial

$5.00

I-Mab Expects Resolution of China-US Auditor Conflict without De-Listings

$5.00

MediLink Raises $70 Million in B Round for ADC Portfolio

$5.00

Shanghai Impact Closes D1 Round for Synthetic Lethality Drugs

$5.00

Three China-Based Biopharmas Receive US De-listing Notices

$5.00

Gan & Lee Starts US Trial of GLP Therapy for Type 2 Diabetes

$5.00

WuXi AppTec Partners to Offer Services with UK's Orbit Discovery

$5.00

Eucure-Biocytogen Start Trial of Dual Drug Combo for Solid Tumors

$5.00

China Approves VR Therapy as Medical Device for Acrophobia

$5.00

J&J in Partnership Talks with Two China Biopharmas

$5.00

Tencent Co-Leads $67 Million Financing for UK's Microbiotica

$5.00

SalubrisBio Raises $32 Million from China Parent for Novel Biologics

$5.00

Nuance Pharma Acquires Rights to Nasal Spray in $23.5 Million Deal

$5.00

InxMed Raises $50 Million for Resistance-Fighting Cancer Therapies

$5.00

OBiO Signs MOU to Manufacture Cell Therapy for Korea's Eutilex

$5.00

Haisco In-Licenses Oral Film Version of Riluzole for ALS

$5.00

Adagene to Add Masking Technology to 4 Sanofi Candidates in $2.5 Billion Deal

$5.00

Zhongze In-licenses CNS Candidate for Schizophrenia and Parkinson's

$5.00

Legend-Janssen CAR-T Therapy Approved in US for Multiple Myeloma

$5.00

AnHeart-Innovent Granted China Breakthrough Status for NSCLC Drug

$5.00

Huadong Strikes $1 Billion Deal for Asia Rights to Four ADC Candidates

$5.00

Transcenta Starts Phase II Trial of Claudin18.2 Therapy for Biliary Tract Cancer

$5.00

CANbridge to Launch Rare Disease Therapy in China's Medical Tourism Zone

$5.00

Simcere Reports Anti-Neutropenia Oncology Drug Meets Phase III Endpoint

$5.00

Huadong Pharma Forms $662 Million Collaboration for Anti-Inflammatory Drugs

$5.00

Lepu Completes $116 Million HK IPO; Trades Flat in Opening Sessions

$5.00

Sirnaomics Says siRNA Effective in Phase II Basal Cell Carcinoma Trial

$5.00

SyMap Starts China Trial of Renal Denervation Device for Hypertension

$5.00

Odeon Acquires China Rights for Two Cancer Therapies in $200 Million Deal

$5.00

Stemirna Planning Phase III Trial of COVID mRNA Vaccine in Brazil

$5.00

Innovent Says China Trial Started for Claudin 18.2 CAR-T Cell Therapy

$5.00

Revotek Starts Trial of Stem Cell 3D Printing Product for Arterial Disease

$5.00

TransThera to Start US Trials of Novel BTK Inhibitor

$5.00

Legend Halts US Trial of CD4+ CAR-T after First Patient Dosed

$5.00

Innovent Reports PCSK-9 mAb Meets Endpoint in Hypercholesterolemia Trials

$5.00

Gracell's BCMA/CD19 CAR-T Starts China Trial for Non-Hodgkin's Lymphoma

$5.00

Sirnaomics Ok'd to Start US Trials of siRNA Therapy for Rare Disease

$5.00

SciNeuro Teams Up with Alamar to Discover Novel CNS Drugs

$5.00

AffaMed In-licenses Rights to AMD Therapy, Approved to Start US Trials

$5.00

IASO/Innovent BCMA CAR-T Granted US Orphan Status for Myeloma

$5.00

CStone Approved to Market Precision Medicine Drug for AML Patients

$5.00

Everest Approved to Launch Triple-Negative Breast Cancer ADC in Singapore

$5.00

Innovent/Lilly PD-1 Rejected by US FDA Panel; Lilly Says Price 40% Below Competition

$5.00

Zerun Bio Lands CEPI Grant to Start Trials of Multi-Variant COVID Vaccine

$5.00

Innovent/Lilly Face US FDA Setback Due to China-Only PD-1 Trials

$5.00

Huadong Med Acquires Rights To Bi-functional Immunotherapy in $75 Million Deal

$5.00

EdiGene to Discover Stem Cell/Natural Killer CAR Therapy for Neukio

$5.00

Ascletis Approved to Start US Trials of an Oral PD-L1 for Solid Tumors

$5.00

CANbridge Says C5 mAb Effective in Early Trial for Complement Diseases

$5.00

Antengene Approved to Start Trial of Oral CD73 Inhibitor for Solid Tumors

$5.00

Xvivo Perfusion Approved to Launch Lung Transplant Product in China

$5.00

Hutchmed Starts China Trial of Novel FGFR Inhibitor in Solid Tumor Cancers

$5.00

Kintor Starts US Trial of Topical Androgen Inhibitor for Alopecia

$5.00

Beroni Group to Build Biopharma R&D Facility in Zhuhai Park

$5.00

Dizal Pharma Awarded US Breakthrough Status for NSCLC Therapy

$5.00

HanBio Raises $40 Million for BiSpecific Antibody Portfolio

$5.00

Akeso Starts Phase III Trial of Bispecific Immunotherapy for NSCLC

$5.00

Xbiome Signs $139 Million China Deal for Probiotic Diabetic Foot Ulcer Therapy

$5.00

I-Mab Partners with Hangzhou Qiantang Park to Build Manufacturing Plant

$5.00

Ractigen Closes $30 Million Financing for RNAa Candidates

$5.00

Grand Pharma Acquires Rights to Mitral Valve Replacement Device

$5.00

Biotime In-licenses Five Adlai Nortye Candidates in $32 Million Deal

$5.00

Ignis Acquires China Rights for ADHD Therapy Device from NeuroSigma

$5.00

Cure Genetics Raises $60 Million to Advance Universal CAR-T Products

$5.00

ImmVira Manufacturing Virus Vectors to Enable Solid Tumor CAR-T Products

$5.00

EdiGene Forms Translational Stem Cell Collaboration with Haihe Lab

$5.00

Applied Pharmaceutical Science to Start US Trial of 2nd Gen RET Inhibitor

$5.00

Eluminex Acquires Global Rights to Therapy for Rare Genetic Blindness

$5.00

Elpiscience Starts US Trial of Novel CD39 Immunotherapy

$5.00

Mabwell Stages $547 Million IPO on STAR Board for Antibody Portfolio

$5.00

Neurophth Approved to Start Gene Therapy for Hereditary Neuropathy

$5.00

Novotech Raises $255 Million to Expand Asia-China Clinical CRO Operations

$5.00

CStone Says PD-L1 Meets Overall Survival Endpoint for NSCLC

$5.00

Abbisko Forms $258 Million Collaboration with Lilly for Cardiometabolic Candidates

$5.00

Innovent Options China Rights to Amagma's Inflammatory Disease Inhibitors

$5.00

JYSSBio Closes B+ Round for Single-Use Bioreactor Manufacturing

$5.00

Thousand Oaks Bio Completes $235 Million Round for CDMO Ops

$5.00

CARsgen's Claudin18.2 CAR T-Cell Candidate Granted US RMAT Designation

$5.00

Fosun and Insilico Collaborate to Develop Five Candidates

$5.00

Accuredit and N1 Life Form JV to Develop Gene Editing Delivery Technologies

$5.00

Shanghai ZhenGe Completes $100 Million Round for Biologic CDMO Services

$5.00

Sana In-Licenses BCMA CAR Construct from IASO/Innovent in $204 Million Deal

$5.00

Junshi and Coherus Enter $290 Million Agreement for Junshi's TIGIT Antibody

$5.00

Junshi Collaborates With DotBio to Discover Multi-Specific Antibodies

$5.00

Akeso Approved for China Trial of Dual PD-1 Bi-Specifics Therapy

$5.00

Nuance Acquires Sino Health in a Deal Worth at Least $32 Million

$5.00

Clover Bio Starts Construction of R&D Center in Zhangjiang Hi-Tech Park

$5.00

Accro Raises $50 Million for Regulated Cell Death Drug Candidates

$5.00

Jiangsu Atom Closes $45 Million Round for Global Phase III Gout Trial

$5.00

AffaMed Signs $145 Million Agreement for China Rights to Ophthalmic Drug

$5.00

Sperogenix In-licenses Rare Disease Treatment in $124 Million Deal

$5.00

Xuanzhu, a Novel Drug Subsidiary of Sihuan Pharm, Completes $96 Million Round

$5.00

CStone Approved for US Trial of ROR1 ADC

$5.00

Amador Bio Raises $60 Million for Translational/Pharmacology CRO Services

$5.00

Great Bay Bio Raises $10 Million for AI CMC Biologic Services

$5.00

Sirnaomics Raises for RNA Therapy in $64 Million in Hong Kong IPO

$5.00

ArkBio In-licenses Novel ADHD Drug in $105 Million Agreement

$5.00

SyMap Closes $100 Million Round for Renal Denervation Devices

$5.00

Biosyngen Opens Cell Therapy Production Facility in Guangzhou

$5.00

Innogen Pharma Closes $120 Million Financing for GLP-1 Diabetes Treatment

$5.00

CStone Announces Hong Kong Approval of Precision Medicine for GIST

$5.00

Tasly Acquires China Rights to Sutro ADC in $385 Million Agreement

$5.00

Kintor COVID-19 Candidate to Target Higher Risk Patients

$5.00

BeiGene Launches Guangzhou Innovation Center for Drug/Device Startups

$5.00

GeneSci In-licenses Alzheimer's Patch Therapy from Luye Pharma

$5.00

Nuance Announces $213 Million Deal for China Rights to Inhaled RDS Therapy

$5.00

ArriVent and Aarvik Form $100 Million Partnership to Develop Oncology Drug

$5.00

Ji Xing In-licenses Cytokinetics Heart Failure Drug in $400 Million Pact

$5.00

Suzhou's TandemAI Raises $25 Million for AI-Wet Lab Discovery Operations

$5.00

CStone Anti-PD-L1 Approved in China for Non-Small Cell Lung Cancer

$5.00

Zai Lab's Partner Approved for US Launch of Myasthenia Gravis Therapy

$5.00

BeiGene Out-Licenses TIGIT Inhibitor to Novartis in $2.8 Billion Agreement

$5.00

Antengene Approved to Launch XPO1 Inhibitor for Multiple Myeloma

$5.00

Zai Lab Approved to Launch Novel Antibiotic in China for Pneumonia

$5.00

3SBio Acquires China Rights to Numab Immunotherapy

$5.00

Nanjing Biosion Out-licenses Global Rights for Trop2 mAb to OBI Pharma

$5.00

Denovo Discovers Biomarker for Gene Therapy

$5.00

BeiGene Begins Trading on STAR Board; Slides 17% Lower

$5.00

LisenID Says Novel Epigenetics Diagnostic Effective in Early Lung Cancer

$5.00

BeiGene In-licenses Rights To LAG-3 mAb from Leads Bio in $772 Million Deal

$5.00

AnHeart Closes $61 Million Round for Precision Oncology Therapies

$5.00

Qilu Enters $300 Million Deal for Novel RNAi Hepatitis B Therapy

$5.00

Hansoh Acquires Cytopenia Therapy in Agreement Worth up to $190 Million

$5.00

Shanghai Regor Enters $1.5 Billion Deal with Lilly for Metabolic Therapies

$5.00

CANbridge Raises $77 Million in Hong Kong IPO; Shares Trade Lower

$5.00

Avistone of Beijing Raises $200 Million; Will Combine with Pearl Biotech

$5.00

I-Mab and Nhwa Announce Novel Alzheimer's Drug Starts US Trials

$5.00

METiS, a US-China AI Company, Raises $86 Million in Series A

$5.00

Xcovery, a US Affiliate of China's Betta, Acquires Majority Stake in Meryx

$5.00

Innoforce Raises $157 Million for Cell/Gene Therapy and RNA CDMO

$5.00

RareStone In-Licenses China Rights to Obesity Therapy in $75 Million Deal

$5.00

Sciwind In-licenses Sanofi's Portfolio of GIP Agonists for Obesity and Diabetes

$5.00

Lynk Pharma Starts China Trial of RA Treatment

$5.00

Tot Biopharma Approved to Launch Avastin Biosimilar in China

$5.00

MingMed Approved to Start US Trial of Immunotherapy

$5.00

SanReno, a China JV, Formed with $40 Million and Two Kidney Disease Drugs

$5.00

ITabMed Formed as JV to Develop T Cell Engagers; Raises $20 Million

$5.00

Ascentage and Innovent Approved to Launch Leukemia Drug in China

$5.00

BeiGene Raises $3.5 Billion in Shanghai STAR Board IPO

$5.00

Suzhou Abogen Raises $300 Million to Support mRNA COVID Vaccine

$5.00

Ablaze Closes $75 Million Series for Targeted Radiopharmaceutical Therapies

$5.00

Help Therapeutics Raises $25 Million for iPSC Heart Failure/Oncology Therapies

$5.00

3D Medicines Approved to Launch Anti-PD-L1 in China

$5.00

Tongshu Biotechnology Raises $78 Million for Early Cancer Screening Tests

$5.00

Neurophth Closes $60 Million C Round for Ophthalmic Gene Therapies

$5.00